BCRX FINANCIAL STATEMENTS

BioCryst Pharmaceuticals Inc — balance sheet, income statement and cash flow trends

BCRXBioCryst Pharmaceuticals Inc

🇺🇸 USA · NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Value it Duel

Income Statement

Quarterly progression — trailing-twelve-month values

RevenueNet Income

Profit Funnel

Q1 2026 · TTM

Percentages are relative to revenue.

Key Figures

YoY change

Revenue885.7 M $+75.9%

Gross Profit167.3 M $-65.7%

Operating Income-381.8 M $-1,251.1%

EBITDA-373.2 M $-884.3%

Net Income-458 M $—

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
BCRX	75.9%	18.9%	-42.1%	-51.7%
ROVI	-3.4%	63.2%	27.0%	17.8%
BHC	-9.9%	75.9%	60.0%	-13.5%
ECILC	-2.3%	34.3%	14.8%	-3.6%
GENIL	16.3%	23.4%	14.3%	4.0%
HLN	-26.7%	61.5%	25.2%	12.6%
Industry median	7.5%	60.6%	18.2%	4.0%

Company	Rev. Growth	Gross Margin	EBITDA Margin	Net Margin
BCRX	75.9%	18.9%	-42.1%	-51.7%
PBH	-4.3%	54.0%	30.4%	17.5%
SUPN	16.3%	89.4%	6.7%	-3.7%
AMLX	—	—	—	—
ANIP	37.0%	65.9%	25.4%	9.7%
HROW	26.2%	74.1%	11.7%	-5.6%
Industry median	7.5%	60.6%	18.2%	4.0%

Balance Sheet

Quarterly period-end values

Total AssetsTotal LiabilitiesEquity

Capital Structure

Q1 2026

Current Liabilities195.4 M $19%
Long-term Liabilities823.5 M $81%

Key Figures

YoY change

Total Assets465.1 M $-3.1%

Total Liabilities1 B $+9.3%

Total Equity-553.8 M $—

Cash & ST Investments239.3 M $-19.0%

Total Debt858.1 M $+3.5%

Net Debt685.6 M $-5.3%

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
BCRX	1.91	-154.9%	-1.66	-119.1%
ROVI	3.66	17.0%	0.09	72.8%
BHC	1.32	-1,010.0%	3.71	-8.4%
ECILC	1.73	5.9%	-0.10	81.0%
GENIL	1.33	41.0%	1.10	52.6%
HLN	0.92	52.3%	3.50	50.3%
Industry median	2.22	46.3%	1.24	45.7%

Company	Current Ratio	Debt/Equity	NetDebt/EBITDA	Equity/Assets
BCRX	1.91	-154.9%	-1.66	-119.1%
PBH	3.57	55.4%	2.96	53.2%
SUPN	1.96	3.8%	-6.64	71.8%
AMLX	17.85	2.1%	1.86	93.0%
ANIP	3.12	58.3%	0.07	39.5%
HROW	2.48	1,047.4%	6.55	6.8%
Industry median	2.22	46.3%	1.24	45.7%

Cash Flow Statement

Quarterly progression — trailing-twelve-month values

Operating Cash FlowCapital ExpendituresFree Cash Flow

Cash Flow Bridge

Q1 2026 · TTM

Key Figures

YoY change

Operating Cash Flow296.8 M $—

Capital Expenditures2.7 M $+164.3%

Free Cash Flow294.1 M $—

Dividends Paid——

Peer Comparison· Drug Manufacturers - Specialty & Generic

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
BCRX	33.5%	33.2%	0.3%	-64.8%
ROVI	24.4%	15.5%	8.9%	137.0%
BHC	16.2%	11.3%	4.9%	-119.7%
ECILC	13.9%	16.1%	7.1%	-391.0%
GENIL	6.4%	-6.7%	4.8%	162.4%
HLN	12.5%	11.3%	1.2%	99.0%
Industry median	15.2%	11.6%	2.5%	84.3%

Company	CF Margin	FCF Margin	CapEx Ratio	CF/Net Income
BCRX	33.5%	33.2%	0.3%	-64.8%
PBH	24.4%	23.4%	1.0%	139.5%
SUPN	10.7%	10.6%	0.1%	-286.9%
AMLX	—	—	—	80.2%
ANIP	22.6%	17.4%	5.2%	232.7%
HROW	5.7%	5.3%	0.3%	-101.6%
Industry median	15.2%	11.6%	2.5%	84.3%

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on BCRX

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.